The novel β2-selective proteasome inhibitor LU-102 decreases phosphorylation of I kappa B and induces highly synergistic cytotoxicity in combination with ibrutinib in multiple myeloma cells

Johannes Kraus(Kantonsspital St. Gallen), Christoph Driessen(Kantonsspital St. Gallen)
Cancer Chemotherapy and Pharmacology
June 22, 2015
Cited by 21


Related Papers